Health IT

Minnesota increases bill for health insurance exchange by 25% in first year, 38% in second

ST. PAUL, Minn. — Minnesota’s state health insurance exchange will cost $54 million in 2015 to operate, according to the Gov. Mark Dayton administration.

The cost comes in at greater than earlier estimates of $30 to $40 million. The state would no…

ST. PAUL, Minn. — Minnesota’s state health insurance exchange will cost $54 million in 2015 to operate, according to the Gov. Mark Dayton administration.

The cost comes in at greater than earlier estimates of $30 to $40 million. The state would not have to find the money until 2015, when the state exchanges are required to be financially self-sustaining. But the cost rises to a projected $64 million in 2016. State officials are still weighing how the exchange will pay for itself. Options include user fees, a sin tax, and selling ads.

The exchange, a cornerstone of the federal health care overhaul, will create an insurance marketplace where consumers and small businesses can comparison shop for health insurance policies starting in October of next year. Coverage would take effect in 2014.

The Dayton administration also announced it will seek an additional $39 million to fund development of the state’s exchange. If the federal government approve the additional grant, Minnesota will have received a total of about $110 million from the feds.

The new financial details emerged earlier this month when the state submitted its application for the exchange to the federal government. 

Many states are behind in their plans for exchanges, and the Obama administration has already agreed to a request by Republican governors for more time to decide whether they’ll build their own state exchange or use the federal alternative. The federal government extended that deadline to Dec. 14.

This story is part of a reporting partnership that includes Minnesota Public RadioNPR and Kaiser Health News.

sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

Kaiser Health News is an editorially independent program of the Henry J. Kaiser Family Foundation, a nonprofit, nonpartisan health policy research and communication organization not affiliated with Kaiser Permanente.